Assistant Professor, Iran University of Medical Sciences, Iran
Dr. Negar Mottaghi-Dastjerdi is an accomplished academic, researcher, and entrepreneur in the field of Pharmaceutical Biotechnology. With a PharmD, Ph.D., MBA, and DBA, she has dedicated her career to the advancement of pharmaceutical sciences and biotechnology. Based at Iran University of Medical Sciences, Dr. Mottaghi-Dastjerdi serves as an Assistant Professor in the Department of Pharmaceutical Biotechnology. She has also excelled in the business sector, serving as the CEO of Persia Vaccine Pharmaceutical and co-founding MehrGene Pharmed. Her diverse experience spans academia, business development, and research advisory, contributing significantly to the biotechnology sector in Iran and beyond.
Profile
Education
Dr. Mottaghi-Dastjerdi holds a Ph.D. in Pharmaceutical Biotechnology from Tehran University of Medical Sciences (2013), where she ranked first with a GPA of 18.81/20. She earned her Pharm.D. from Mazandaran University of Medical Sciences in 2009, also ranking first with a GPA of 18.36/20. She further pursued an MBA in Business Strategy at the University of Tehran, graduating with a GPA of 18.5 in 2019, followed by a Doctorate in Business Administration (DBA) in 2020. Her educational background reflects her commitment to combining scientific expertise with business acumen to drive innovation in biotechnology.
Experience
Dr. Mottaghi-Dastjerdi has extensive experience in both academia and industry. She is currently an Assistant Professor in the Department of Pharmaceutical Biotechnology at Iran University of Medical Sciences (2020–present), where she also leads multiple educational and accreditation committees. Her professional experience includes serving as CEO of Persia Vaccine Pharmaceutical and co-founder of MehrGene Pharmed. She has also held the role of Business Development Manager at MehrGene Pharmed and advised four biotech companies on cell line development, purification, and formulation over the past nine years. Her broad expertise spans research, business management, and teaching.
Awards and Honors
Dr. Mottaghi-Dastjerdi’s achievements have earned her several prestigious awards. She was named “Outstanding Professor” at Iran University of Medical Sciences in 2023. In 2009, she received the “National Outstanding Student” award. She also ranked first in the Ph.D. entrance exam for Pharmaceutical Biotechnology and the Specialty Board Examination in 2011. Her academic excellence is further demonstrated by her top-ranking performances during both her Pharm.D. and Ph.D. studies, where she achieved GPAs of 18.36/20 and 18.81/20, respectively. These honors highlight her exceptional dedication to her academic and professional pursuits.
Research Focus
Dr. Mottaghi-Dastjerdi’s research primarily focuses on Pharmaceutical Biotechnology, cancer genomics, and biopharmaceuticals. Her work involves gene expression profiling, drug resistance mechanisms in gastric cancer, and the development of biopharmaceutical products. She has explored the use of real-time PCR methods for detecting residual DNA in biopharmaceuticals and studied novel genes involved in carcinogenesis. Her interdisciplinary research bridges molecular biology, biotechnology, and pharmaceutical sciences, aiming to develop more effective treatments for cancer and improve the production of biopharmaceuticals. Her research also involves exploring innovative biotechnological solutions for health-related challenges.
Publications
- Gene expression profiling revealed overexpression of vesicle amine transport protein-1 (VAT-1) as a potential oncogene in gastric cancer 🧬
- Selective Inducible Nitric Oxide Synthase Inhibitor Reversed Zinc Chloride-Induced Spatial Memory Impairment 🧠
- Comparison of SYBR Green and TaqMan real-time PCR methods for quantitative detection of residual CHO host-cell DNA in biopharmaceuticals 🧪
- Identification of novel genes involved in gastric carcinogenesis by suppression subtractive hybridization 🧬
- Genome expression analysis by suppression subtractive hybridization identified overexpression of Humanin in gastric cancer chemoresistance 🧬
- Overexpression of FOXO3, MYD88, and GAPDH identified by suppression subtractive hybridization in esophageal cancer 📊
- An insight into the interactions between-tocopherol and chitosan in ultrasound-prepared nanoparticles 🧪